COPENHAGEN, MARCH 24 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that Antibiotx has been rewarded a grant from Innovation Fund Denmark to further explore ATx201’s influence on biomarkers in inflammatory disease.

Specific inflammatory pathways appear to be important for atopic dermatitis severity and ATx201 shows promising assets affecting these pathways. Based on this rationale, Innovation Fund Denmark has granted AntibioTx the means to investigate ATx201 in a well-established clinical model”.

About Atopic dermatitis

Atopic dermatitis is one of the most common skin diseases. It is estimated that 5–20% of the population worldwide is suffering from atopic dermatitis. The disease is believed to develop from a complex interplay of environmental and immunologic factors and is often associated with allergy and asthma. Characteristic AD symptoms are itchy skin (pruritus) and inflammation causing redness, dry skin, crusting, vesicle formation, and swelling. Numerous studies have found that AD has a major impact on physical and psychological well-being and has a psychological impact on close relatives.

This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts and can be identified by words such as committed, will, steps, may, can, portfolio, planned, advancing, look forward, expected, or similar words. These forward-looking statements are based upon current expectations, estimates, believed potentials and can, therefore, involve risks and uncertainties. Many of these risks and uncertainties can be difficult to predict and could be out of the control of AntibioTx A/S. We may not actually achieve our intended plans, and you should not place undue reliance on these forward-looking statements.

Source: Thomas Bieber. Atopic Dermatitis, Mechanisms of Disease. New England Journal of Medicine, 2008